Taxus brings Boston $42million from first 10 days on US market
This article was originally published in Clinica
Executive Summary
Boston Scientific has reported US sales of its Taxus Express2 drug-eluting stent of $42m for the first 10 selling days after its launch. With the number of accounts the company is selling to ramping up rapidly, US Taxus revenues look like they will comfortably meet Boston's expectation of $52-75m for the 23 selling days to March 31.